ArticlePediatric surgery international2025
Meso-Rex shunt revisited: are cryopreserved arterial allografts an alternative to autologous venous conduits?
Article in Pediatric surgery international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeMeso-Rex procedure is the surgical treatment of choice for severe portal hypertension (PHT) secondary to extrahepatic portal vein obstruction (EHPVO). Our aim was to describe our initial experience using cryopreserved arterial allografts as an alternative shunting conduit.
methodsRetrospective review of patients with EHPVO who underwent a Meso-Rex procedure using cryopreserved arterial allografts between January 2023 and April 2024.
resultsRex shunt surgery was performed in five of the eleven patients operated for EHPVO during this period. Arterial allografts were employed in four cases, with a mean age of 10 ± 1.2 years. The mean conduit diameter and length was 9.25 ± 3.5 and 73.5 ± 11.5 mm, respectively. With a mean follow-up of 16 ± 5 months, all patients developed shunt thrombosis secondary to calcification. Shunt flow was reestablished exclusively with percutaneous transhepatic thrombectomy and stenting in one patient. The remaining three patients required a revision surgery to remove the calcified graft: two Rex shunts were salvaged with polytetrafluoroethylene (PTFE) conduits and one was converted to a mesocaval shunt. All shunts are patent 6.5 ± 2.2 months after repermeabilization.
conclusionAlthough the intended use of cryopreserved arterial grafts was to avoid comorbidities associated with harvesting autologous conduits, they are not an alternative to the classic Meso-Rex procedure given the high thrombosis and reoperation rate secondary to shunt calcification.
Indexed as
Identifiers
40652065What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.